Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

Bagi R.P. Jana

doi:10.1016/s1548-5315(11)70531-9

Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

Bagi R.P. Jana

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.

Original language	English (US)
Pages (from-to)	540-542
Number of pages	3
Journal	Community Oncology
Volume	7
Issue number	12
DOIs	https://doi.org/10.1016/s1548-5315(11)70531-9
State	Published - Dec 2010

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/s1548-5315(11)70531-9

Cite this

@article{322685d0db164896b81d20eef3ddbc5f,

title = "Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer",

abstract = "A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.",

author = "Jana, {Bagi R.P.}",

year = "2010",

month = dec,

doi = "10.1016/s1548-5315(11)70531-9",

language = "English (US)",

volume = "7",

pages = "540--542",

journal = "Community Oncology",

issn = "1548-5315",

publisher = "BioLink Communications",

number = "12",

}

TY - JOUR

T1 - Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

AU - Jana, Bagi R.P.

PY - 2010/12

Y1 - 2010/12

N2 - A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.

AB - A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.

UR - http://www.scopus.com/inward/record.url?scp=78651246898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651246898&partnerID=8YFLogxK

U2 - 10.1016/s1548-5315(11)70531-9

DO - 10.1016/s1548-5315(11)70531-9

M3 - Article

AN - SCOPUS:78651246898

VL - 7

SP - 540

EP - 542

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 12

ER -

Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this